Silkim Pharma developed a novel, protected PLATFORM of drugs for proven treatments of
Our PLATFORM is the result of extensive investigation of animal models of human diseases.
Members of our PLATFORM act as:
(i) Potent anti-inflammatory agents,
(ii) Strong iron chelating agents, and
(iii) Anti-biotic agents.
These Modes of Action jointly assist in treating the causes and/or symptoms of multiple indications.
Our PLATFORM enables accelerated expansion from one proven product to another without having to rediscover and re-create a specific underlying technology for each product.
Concenter BioPharma is committed to developing and delivering proven therapies that work harmoniously with the human body and advance the treatment landscape for people with life-threatening diseases.
Potential Clinical Applications include:
CNS Injury and Degenerative Diseases - demonstrated by enhanced recovery of Spinal Cord Injury (mouse); is expected to prove efficient in Multiple Sclerosis, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
Inflammatory skin disorders - extensively demonstrated efficient treatment of irritant contact dermatitis (mouse), and in sporadic human cases of psoriasis, seborrhea dermatitis, , wound healing, and chemical/heat burns.
Inflammatory Pulmonary diseases - demonstrated efficiency in the treatment of Ovalbumin-induced asthma model (mouse); is expected to show high efficiency in human asthma, nasal polyposis, allergic rhinitis, cystic fibrosis (CF), and lung fibrosis.
Type 2 diabetes and its complications - demonstrated in diet-induced diabetes (Sand Rat) by markedly inhibiting the appearance and the degree of hyperglycemia, arresting the conversion of insulin-resistance state to fully-blown diabetes; attenuating cataract formation and diabetes-induced retinopathy. Proved efficient on healing of diabetic foot ulcers (DFU) on human patients.
About Silkim Pharma Ltd.
During the development of the PLATFORM the following milestones have already been realized:
Synthesis of several therapeutic agents – members of the PLATFORM
Chemical characterization of the structure and properties of the two therapeutic agents
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of inflammatory skin diseases
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of nutritionally induced diabetes
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of asthma
Identification of the molecular target of the therapeutic agents via 3 simultaneous modes of action
Identification of NEW members of the PLATFORM of therapeutic agents and partial characterization of their chemical properties and biological activities
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of spinal cord injury
Silkim Pharma has a family of composition-of-matter and methods-for-use patents issued, allowed and pending in the USA, Canada, EU, Australia, Mexico, China, Israel, Japan, Korea, Singapore, India, Hong Kong.